CRYSTAL FORMS OF LOMEFLOXACIN: PREPARATION, CHARACTERIZATION AND DISSOLUTION PROFILE

Vellaichamy Ganesan; Raju Thenge; Naresh Vinjamuri; Srinivasarao Prathipati

doi:10.14499/indonesianjpharm0iss0pp238-244

CRYSTAL FORMS OF LOMEFLOXACIN: PREPARATION, CHARACTERIZATION AND DISSOLUTION PROFILE

Vellaichamy Ganesan, Raju Thenge, Naresh Vinjamuri, Srinivasarao Prathipati

Abstract

The present work was undertaken with the synthesis of crystal forms of Lomefloxacin from solvents of varying polarity (polar, protic solvents). The purpose of the present investigation was to employ crystallization techniques in order to improve the solubility and dissolution studies of Lomefloxacin. The experimental methods involved the preparation of lomefloxacin crystals by crystallization from single solvent technique. Crystals were prepared from solvents like distilled water, ethanol and methanol. Prepared crystals were undergone various studies in terms of crystal yield, melting point, true density, solubility and in vitro drug release study as well as characterized by technique viz: FT-IR, differential scanning calorimetry (DSC) and Powder X-ray Diffractometry(PXRD). Photomicrographs of the crystals shows that the crystals obtained from different solvents existed in different shape. Among all the crystals, LOME-I belongs to Type-1 and LOME–II belongs to Type-2 based on instrumental techniques. Highest crystal yield (88%) and maximum density (1.2021g/mL) was observed with LOME-I. Maximum solubility and dissolution rate was observed in LOME-III followed by LOME-II and LOME-I. However all prepared crystal forms showed higher solubility and dissolution profile when compare with commercial Lomefloxacin. It is concluded that the study has indicated the existence of two polymorphic forms of Lomefloxacin which was having better solubility and in vitro release than that of commercial Lomefloxacin.
Key words: Polymorphism, Solubility, Dissolution rate, DSC, FT-IR, PXRD

Full Text:

Untitled

References

Babu NJ. and Nangia A., 2011, Solubility advantage of amorphous drugs and Pharmaceutical co crystals. Cryst. Growth Des11(7): 2662-2679.

Brittain HG., 1999, Polymorphism in Pharmaceutical Solids Newyork: Marcel Dekker. 1 – 9.

Brittain HG., 2005, Analytical Profiles of Drug substance and Excipients, Academic Press New Delhi, Vol. 23: 321 - 369.

Brittain HG., 2012, Polymorphism and Solvatomorphism, J Pharm Sci., 101(2): 464-484.

Gomes GC. and Salgado HRN., 2005, Validation of UV Spectrophotometric method for determination of Lomefloxacin in pharmaceutical dosage form. Acta Farm. Bonaerense, 24 (3): 406 – 408.

Lin SY., 2007, Grinding and compression processes affecting the solid-state transition of famotidine polymorphs. Asian. J. Pharm. Sci, 2 (5): 211- 219.

Yadav MR.,. Shalkh RA, Ganesan V., Giridhar R., Chadhu R., 2008,. Studies on the Crystal Forms of Pefloxacin: Preparation, Characterization and Dissolution Profile. J .Pharm. Sci, 97 (7): 2637 –2648.

Petra D., Janez K., Gerald G., Iztock T., 2006, X-ray crystallographic, NMR and Antimicrobial activity of magnesium complex of Fluoroquinolones racemic Ofloxacin and its S-form Levofloxacin. J. Inorg. Bio. chem, 100:1755 – 1763.

Prajapati T., Patel P., 2010, Influence of different solvents on crystal property and solubility characteristics of Carbamazapine. Int. J. Pharm. Tech. Res,; 2(2): 1615 - 1624.

Puigjaner C., Barbas R., Prohens R., 2007, A New polymorph of Norfloxacin complete characterization and relative stability of its trimorphic system, J. Thermal Analysis and Calorimetry; 89 (3):687 – 692.

Shariare MH., Leusen FJJ., De Matas M., York P., Anwar J., 2012, Prediction of the mechanical behavior of crystalline solids. Pharm. Res. 29(1):319-331.

Sohn YT., Kim SH., 2008, Polymorphism and Pseudopolymorphism of Acyclovir. Arch. Pharm. Res, 31 (2): 231 - 234.

Talari R., Varshosaz J, Mostafavi SA, Nokhodchi A, 2009, Dissolution Enhancement of Gliclazide using pH Change Approach in Presence of Twelve Stabilizers with Various Physicochemical Properties. J. Pharm. Pharmaceut. Sci, 12(3): 250 - 265.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp238-244